Look up one drug

Reason for Use code 371 For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B. Coverage limit: Network will limit supply to 6 weeks. Coverage limit: *The outbreak must be confirmed by Public Health. Coverage limit: LU Authorization Period: 1 year Reason for Use code 372 For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis. Coverage limit: Network will limit supply to 5 days. Coverage limit: *The outbreak must be confirmed by Public Health. Coverage limit: LU Authorization Period: 1 year Reason for Use code 639 For treatment of individuals who are at high risk* of complications from influenza infection and have either: 1. Laboratory-confirmed influenza A or influenza B infection; OR 2. Illness consistent with influenza A or influenza B infection *High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics: - Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema - Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease - Renal disease - Chronic liver disease - Diabetes mellitus and other metabolic diseases - Anemia and hemoglobinopathies, such as sickle cell disease - Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders) - Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders) - Children aged younger than 5 years - Individuals aged 65 years or older - Individuals of any age who are residents of nursing homes or other chronic care facilities - Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended - Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender - Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid - Indigenous peoples Maximum dosage: 75mg twice daily for 5 days Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits. Coverage limit: LU Authorization Period: 6 Months Coverage limit: Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mint-Oseltamivir · DIN 02497476 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-07-31 Health Canada: Marketed since 2023-10-18 · brand MINT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Mint pharmaceuticals inc · schedule Prescription

DIN 02497476: Mint-Oseltamivir Raw flags: sec12=Y, sec3=Y Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id MIN Source form: Cap; strength: 75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0393; ministry $1.0393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497476 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98729

Interchangeable products

Jamp Oseltamivir · DIN 02497425 · $1.0393 Nat-Oseltamivir · DIN 02457989 · $1.0393 Sandoz Oseltamivir · DIN 02504022 · $1.0393 Tamiflu · DIN 02241472 · $1.0393

Shortage status: resolved shortage (ended 2023-10-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497476

Shortage record checked 2026-09-13T08:10:21.292534+00:00